COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact

COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact

Abstract Trial results for two COVID-19 vaccines suggest at least 90% efficacy against symptomatic disease (VEDIS). It remains unknown whether this efficacy is mediated by lowering SARS-CoV-2 infection susceptibility (VESUSC) or development of symptoms after infection (VESYMP). We aim to assess and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: David A. Swan, Chloe Bracis, Holly Janes, Mia Moore, Laura Matrajt, Daniel B. Reeves, Eileen Burns, Deborah Donnell, Myron S. Cohen, Joshua T. Schiffer, Dobromir Dimitrov
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/2eab7a70fea74c65a94d95d63fb05ed5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares